



MedAdvisor Limited
ACN 145 327 617
Level 2, 971 Burke Road
Camberwell Vic 3124
mymedadvisor.com/investors

ASX RELEASE (ASX: MDR)

MedAdvisor expands US digital platform network

Melbourne, Australia, 28 November, 2022 – Medtech company, MedAdvisor Limited (**MedAdvisor** or the **Company**) (ASX:MDR) is expecting a larger than usual seasonal increase in usage of its US-based digital platform, inMotion, as the flu season in the US kicks in and the COVID-19 awareness program expands through to the end of 2022.

MedAdvisor has increased digital access to patients by 50 percent in the US through additional pharmacy support of the inMotion digital communications solution. It recently signed an inMotion agreement with a pharmacy software group representing over 10,000 pharmacies in the US, for an initial two year term (followed by automatic one year renewal terms unless either party opts to not renew). This, in combination with additional national and regional pharmacy groups now supporting inMotion, has increased MedAdvisor's US network from around 20,000 to over 30,000 pharmacy locations with an ability to reach over 60 million individuals via the inMotion digital communications solution. The Company notes that, whilst this agreement will not of itself increase revenue, it may indirectly do so by providing the increased network for the provision of MedAdvisor's programs.

Due to the success of the COVID-19 awareness program announced on 1 November 2021 and rolled out in the first half of 2022, that top 10 pharmaceutical manufacturer has extended its program across the US through the rest of 2022. This extension is fueled by the combination of the expansion of the US pharmacy network, increased support of inMotion, and the 2022 flu season.

MedAdvisor expects revenue to increase in line with escalating platform use, which has already positively impacted the company's Q1 FY23 results and will do so again in Q2 FY23.

CEO & Managing Director Rick Ratliff, said:

"Medadvisor is about to see the benefits of its technology platform's ability to scale as we head into the colder months in the United States. Over the last 12 months we have significantly increased the number of pharmacy locations in the US with access to our digital platform and digital programs, now numbering over 30,000. This has expanded our digital reach by 50 per cent to 60 million Americans that now have access to digital communications from their local pharmacy.

"In addition, our ongoing COVID-19 vaccination awareness program has produced solid results with click through rates higher than industry averages. As a result, this program is being extended through to the end of 2022.

"We expect these factors to drive the Company's financial performance in the first half of FY23."

- ENDS -

This document has been authorised for release by the CEO & Managing Director of MedAdvisor Limited.

For more information:

Company

Rick Ratliff, CEO & Managing Director
corporate@medadvisor.com.au

Investors

Ronn Bechler
ronn.bechler@atomicgroup.com.au
+61 400 009 774

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers patients to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects patients to tools and education materials from their preferred pharmacy. MedAdvisor works with 25,000 pharmacies in the US to deliver programs to help patients take their medication safely and effectively. In Australia, MedAdvisor has connected over 2.9 million patients through more than 90% of Australian pharmacies. MedAdvisor is on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors